Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions about the breakthrough therapies of the…

“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

As the biotech industry advances scientific discovery around new tumor types and mechanisms of action, we’ve seen more than 2,000 combination trials launched to enhance PD-1/L1 checkpoint inhibitors’ effects on solid tumors. The oncology pipeline has some exciting new biotechnological approaches…

At the time this blog was published, the coronavirus had taken more than 500 lives across the globe and infected more than 28,000 people across 25 countries. While these numbers are alarming, hope is on the horizon – and America’s biopharmaceutical industry is leading the charge.  In a…

BIO’s Industry Analysis team has published its 5th report in a series on the innovation landscape of highly prevalent, chronic diseases. This new report [available here] reviews the state of drug development for hypertension and heart failure. As with the prior reports, the investigation into these…

The rapid spread of the coronavirus out of Wuhan, China has sparked concern across countries as the international community grapples with how best to contain it. The clock is ticking to find a solution. Luckily, innovative biotechnology companies are working tirelessly each today to heal the world…

Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.”  It’s a conversation that should be transparent and open to everyone,…

The 340B Drug Discount Program is in the spotlight with the release of a new report from the Government Accountability Office (GAO) calling attention to oversight of the program designed to help vulnerable patients gain access to affordable prescription drugs. As the findings show, the program,…

Rick Starrs, CEO of NAVREF When it comes to clinical research trials, America leads the world in providing patients with access to the latest, state-of-the-art care. However, an under-represented population in clinical studies might surprise you: veterans. To correct this shortfall,…